Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Datametrex will be providing the 1copy™ COVID-19 qPCR Multi Kit to test crew members, onboard performers, technicians and stagehands
  • The testing will commence September 30th continuing into the first quarter of 2022
  • Datametrex AI Limited is a technology-focused company
  • Datametrex AI Limited (DM) opened trading at C$0.175 per share

Datametrex (DM) has entered into a COVID-19 testing service agreement for a cruise line operated by one of the world’s largest entertainment companies.

Datametrex will be providing the 1copy™ COVID-19 qPCR Multi Kit, that can identify the new variants of COVID-19, for use in testing officers, crew performers, directors, choreographers, audio technicians, stagehands, and costume technicians at the Toronto area rehearsal facility.

The testing will commence September 30th continuing into the first quarter of 2022 and will increase each month until the full entertainment operations are hired and trained.

Marshall Gunter, CEO of Datametrex commented on the agreement.

“This new testing service for the cruise industry gets our feet in a new revenue stream. When the pandemic hit in March 2020, cruise ships were particularly hit hard, which brought the industry to a halt worldwide stranding over 50 cruise lines and more than 270 ships. In an industry worth approximately $150 billion, and 1,177,000 jobs equaling $50.24 billion in wages and salaries, it is important to test crew regularly to minimize the threat of a shutdown again.”

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy.

Datametrex AI Limited (DM) opened trading at C$0.175 per share.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.